Skip to main
ALMS
ALMS logo

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc’s innovative approach to treating autoimmune disorders is bolstered by its promising pipeline, particularly with A-005 demonstrating complete disease suppression in relevant models and exhibiting a favorable pharmacokinetic profile. The ongoing merger with Acelyrin is viewed positively by the Acelyrin board, indicating confidence in maximizing long-term value, which may enhance Alumis’s market position. Furthermore, ESK-001's updated efficacy data suggests strong potential market penetration that could surpass competition, further solidifying a favorable outlook for Alumis's future financial performance.

Bears say

Alumis Inc faces significant risks that contribute to a negative outlook on its stock, particularly concerning the advancement of its lead candidate, ESK-001, into pivotal trials, which could be delayed. There are substantial concerns regarding the clinical efficacy of ESK-001 in psoriasis (PsO) and systemic lupus erythematosus (SLE) trials, alongside hurdles in securing regulatory approvals in key markets that are critical for revenue generation. Furthermore, the competitive landscape within the immunology and inflammation (I&I) therapeutic sector poses additional threats, compounded by the potential for slower-than-expected market uptake and dilution risks affecting shareholder value.

Alumis Inc (ALMS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 4 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.